Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.96
-0.1032-0.29%
Post-market: 35.000.0428+0.12%16:10 EDT
Volume:2K
Turnover:66.28K
Market Cap:16.43M
PE:- -
High:35.10
Open:35.10
Low:34.96
Close:35.06
52wk High:37.90
52wk Low:28.87
Shares:469.95K
Float Shares:469.95K
Volume Ratio:0.73
T/O Rate:0.40%
Dividend:0.41
Dividend Rate:1.17%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Johnson & Johnson Announces R$ 0.3 Per Unit Dividend for 3Q 2026

Reuters
·
Sep 10

Optimi Health to initiate Phase 2 trial of psilocybin-assisted therapy for MDD

TIPRANKS
·
Sep 10

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

Novartis shareholder calls for board changes, Reuters reports

TIPRANKS
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001

GlobeNewswire
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10

Johnson & Johnson receives CE Marking for ACUVUE OASYS MAX

TIPRANKS
·
Sep 10

Market Chatter: Novartis Shareholder Urges Board Changes After Trial Failures

MT Newswires Live
·
Sep 10

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS
·
Sep 10

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

GlobeNewswire
·
Sep 10

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

Market Wrap September 10: Innovation Drug Shares Dip Amid Clinical Setback, Bank Stocks Post Modest Gains

Stock News
·
Sep 10

Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy

TIPRANKS
·
Sep 10